Risk factors
Arbutus Biopharma (ABUS) risk factors
Item 1A of every Arbutus Biopharma Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors41 risks4 new5 dropped13 reworded
Moderna litigation and the potential $1.3 billion contingent payment now dominate the risk section.
Filed Mar 23, 2026 - FY2024 10-K risk factors42 risks
Arbutus Biopharma faces intense patent litigation with Moderna and Pfizer while undergoing major management turnover and a 57% workforce reduction. The company relies heavily on partners like Alnylam and Qilu while clinical development remains early-stage.
Filed Mar 27, 2025